Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Hyperaldosteronism
  • Prostatic Neoplasms

abstract

  • AA plus prednisone was well tolerated, with encouraging antitumor activity in heavily pretreated CRPC patients. The incidence of mineralocorticoid-related toxicities (hypertension or hypokalemia) was reduced by adding low-dose prednisone. The combination of AA plus prednisone is recommended for phase III investigations.

publication date

  • March 20, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3040042

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.9259

PubMed ID

  • 20159814

Additional Document Info

start page

  • 1496

end page

  • 501

volume

  • 28

number

  • 9